Prime Medicine, Inc. — FY 2022 Form 10-K
Reporting period: Fiscal year ended December 31, 2022. This is an annual report; the filing does not provide a clear standalone fourth-quarter financial summary. Prime Medicine is a preclinical biotechnology company developing Prime Editing genetic therapies. It reported no product revenue and had not begun clinical development.
Financial and operating performance
| Metric | FY 2022 | FY 2021 |
|---|---|---|
| Revenue | $0 | $0 |
| Research and development expense | $86.7 million | $70.6 million |
| General and administrative expense | $29.8 million | $13.9 million |
| Total operating expenses | $116.5 million | $84.5 million |
| Net loss | $121.8 million | $165.4 million |
| Net cash used in operating activities | $131.8 million | $34.1 million |
| Cash, cash equivalents, short-term investments and related-party short-term investment | $293.9 million, excluding restricted cash | — |
At year-end, restricted cash was $13.5 million; total cash, cash equivalents and restricted cash were $201.1 million. The company reported no debt outstanding. Gross margin and profitability metrics are not meaningful for this pre-revenue business.
Management estimated existing cash and investments would fund operating expenses and capital expenditures into 2025, while cautioning that plans could change and additional financing may be needed. The company completed its October 2022 IPO, receiving $180.2 million in net proceeds; it said the proceeds had not been used as of year-end.
Material changes versus the prior year
- Net loss narrowed by $43.5 million, chiefly because FY 2021 included $81.0 million of non-cash expense from changes in the fair values of preferred-stock tranche and anti-dilution liabilities, which were settled in 2021. Operating expenses nevertheless rose $32.1 million.
- R&D expense increased $16.2 million, primarily from expanded laboratory activity, hiring and facilities; the comparison also reflects $42.0 million of Myeloid-related acquired in-process R&D expense recorded in 2021.
- G&A expense increased $15.9 million, including higher personnel, professional, public-company and facility costs.
- Operating cash use increased to $131.8 million, partly reflecting the $30.0 million Myeloid upfront cash payment in January 2022 and higher operating activity. Investing cash use was $47.1 million, including $16.1 million of property and equipment purchases.
- The company became public in October 2022; preferred stock converted into common stock in connection with the IPO.
Business progress, outlook and risks
- The company reported a portfolio of 18 investigational programs, including one partnered with Beam Therapeutics. Its most advanced described program was chronic granulomatous disease: it selected development candidate PM359 and planned to begin IND-enabling studies. The filing describes all in-vivo studies as preliminary.
- Management planned additional rodent and non-human-primate preclinical work in 2023. If successful, the company said a first IND filing could occur as early as 2024, with additional filings potentially as early as 2025. These are targets, not assured outcomes.
- Reported preclinical findings included correction and functional readouts across several programs, but Prime Editing had not been clinically validated and no product candidate had entered clinical trials. The company’s estimate that the platform could address approximately 90% of known disease-causing mutations is theoretical, not demonstrated clinical reach.
- Key risks include technical efficacy and delivery, off-target or other safety effects from permanent genome edits, uncertain regulatory requirements, manufacturing scale and quality, intellectual-property scope and licensing obligations, competition, and the need for substantial additional capital. The company expects continued losses and may never achieve profitability.
- Commitments include a $5.0 million annual Broad Institute/Harvard research pledge for 14 years beginning in 2021, subject to termination terms; existing recognized operating-lease payments of $30.8 million; and an uncommenced 60 First Street lease expected to cost approximately $208.7 million over ten years. Myeloid option exercise would require $80.0 million in cash plus shares valued at $30.0 million; the option had not been exercised at year-end.
- The company recorded an $8.1 million loss in 2022 from the fair-value change in its Beam equity investment. It also recognized a $0.9 million income-tax benefit and maintained a full valuation allowance on net deferred tax assets, except for amounts supported by deferred tax liabilities.
Important facts for investors to verify
- Cash runway assumptions and the timing, scale and terms of any future financing.
- Progress of PM359 and other programs through in-vivo validation, IND-enabling studies and regulatory review; confirm that preliminary results translate into reproducible, clinically relevant outcomes.
- Evidence supporting editing precision, durability, delivery, safety and off-target assessments, including the limitations of preclinical assays.
- Material license and collaboration terms, including Broad Institute rights and milestones, the Beam partnership economics, and whether Prime Medicine exercises the Myeloid option.
- Lease and other long-term commitments, including commencement and cash obligations for the 60 First Street facility.